A sensitive and selective ultra-high performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method for the simultaneous determination of seven oral oncolytics (two PARP inhibitors, i.e. olaparib and niraparib, and five tyrosine kinase inhibitors, i.e. cobimetinib, cabozantinib, dabrafenib, vemurafenib and regorafenib, plus its active metabolite regorafenib M2) in EDTA plasma was developed and validated. Stable isotope-labelled internal standards were used for each analyte. A simple protein precipitation method was performed with acetonitrile.
| INTRODUCTION
Over the last two decades, the development of targeted oral anticancer drugs has increased strongly and this is expected to continue.
After the approval of the first oral tyrosine kinase inhibitor imatinib in 2001, various oral kinase inhibitors have been approved, specifically targeting one or multiple protein kinases (Dagher et al., 2002; Roskoski, 2019) . Protein kinases play a key role in activating proteins that are involved in signal transduction pathways that regulate cell survival, proliferation and differentiation. In patients with malignancies, these pathways are often upregulated as they drive tumour growth, proliferation and angiogenesis (Ardito, Giuliani, Perrone, Troiano, & Lo Muzio, 2017) . Hence, inhibitors of protein kinases in these pathways comprise an important therapeutic intervention (Zhang, Yang, & Gray, 2009 ). Protein kinase inhibitors that have been approved recently and are used in our clinic include vemurafenib, dabrafenib, cobimetinib, regorafenib and cabozantinib. Recently, a new group of targeted oral anticancer drugs was introduced. Olaparib and niraparib are inhibitors of the poly ADP ribose polymerase 1 (PARP-1). PARP is essential for the repair of single-strand DNA breaks via the base excision pathway. Inhibiting PARP results in doublestrand DNA breaks which result in cell death (Ashworth, 2008) .
Although PARP inhibitors were initially intended for use in cancers driven by BRCA1 or 2 mutations, these drugs are now also being investigated for use in homologous repair-deficient tumors lacking BRCA1 and 2 mutations and in combination with chemotherapy or radiation to enhance the DNA-damaging effects (Cesaire et al., 2018; Lu, Liu, Pang, Pacak, & Yang, 2018) .
PARP inhibitors and tyrosine kinase inhibitors are registered in a fixed dose, which means each patient receives the same dose regardless of body size differences. For some of these drugs, a clear relationschip between drug exposure and efficacy has already been described. For instance, for patients treated with cabozantinib, greater antitumour acitivity was observed for patients with a steady-state concentration >750 μg/L (Lacy et al., 2018) . For vemurafenib, a lower risk of disease progression was seen for patients with a median plasma concentration of 42,000 μg/L during the first year of treatment (Goldwirt et al., 2016) . Patients treated with these drugs will probably benefit from routine therapeutic drug monitoring to achieve these target levels. For the other drugs, the relationship between drug exposure and response needs to be further elucidated. In addition, measuring the exposure of these drugs can be of help for dose adjustment decisions in the presence of drug-drug interactions or co-morbidities, as these drugs have a narrow therapeutic window and high inter-patient variability.
Therefore, there is a need for pharmacokinetic evaluation both in clinical studies and for individual patients. Our laboratory has previously implemented a bioanalytical method for the measurement of imatinib, sunitinib, desethyl sunitinib and pazopanib in a single run for routine patient care and clinical studies (van Erp et al., 2013) . Since novel oral oncolytics have become available, an additional method had to be developed to analyse these drugs, preferably in a single run.
Numerous LC-MS/MS methods have been described for quantification of the individual compounds or a combination of cobimetinib (Cardoso et al., 2018; Deng et al., 2014; Huynh et al., 2017; Rousset et al., 2017) , cabozantinib (Abdelhameed, Attwa, & Kadi, 2017) , dabrafenib (Cardoso et al., 2018; Huynh et al., 2017; Merienne et al., 2018; Rousset et al., 2017 ), niraparib (van Andel et al., 2017 , olaparib (Nijenhuis, Lucas, Rosing, Schellens, & Beijnen, 2013; Pressiat et al., 2018) , vemurafenib (Cardoso et al., 2018; Huynh et al., 2017; Nijenhuis, Rosing, Schellens, & Beijnen, 2014; Rousset et al., 2017) and regorafenib (Cardoso et al., 2018; Huynh et al., 2017; Luethi et al., 2014; Merienne et al., 2018; van Erp et al., 2013) in human plasma.
However, a quantification method combining all of the above mentioned oncolytics in a single run has not been published yet.
Our objective was to develop and validate a sensitive and selective bioanalytical method by ultra-high performance liquid chromatog- 
| Chromatographic conditions
The LC-MS 
| Mass spectrometric conditions
The mass spectrometer was run in the positive ion mode and configured in multiple reaction monitoring mode for detection of RGF, RGF M2, OPR, VMF, CBT, NRP, CBZ, DBF and their isotope-labelled analogues. Figure 1 shows the chemical structures of all eight analytes and their selected mass transitions and proposed m/z fragments. 
| Sample preparations
Samples were mixed for 5 min and subsequently centrifuged for 5 min at 19,000g. Protein precipitation as sample preparation was performed by adding 200 μl of the precipitation reagent to 50 μl of EDTA plasma into a 1.5 ml polypropylene microcentrifuge tube. After vortex-mixing for 2 min, samples were centrifuged for 5 min at 19,000g. A volume of 20 μl of the supernatant was transferred to an autosampler vial, diluted 10-fold with water and vortex-mixed for 5 min. Subsequently, 10 μl was injected into the UPLC-MS/MS.
| Validation procedures
Method validation was performed in accordance with the "Guideline on bioanalytical method validation" of the European Medicines Agency (EMA) (EMA, 2012).
| Selectivity and carryover
Interference from endogenous compounds was investigated by analysing blank human EDTA plasma samples of six different individuals.
Absence of interfering components was accepted when the response was <20% of the lower limit of quantification (LLOQ) for all analytes and <5% for the IS.
Carryover was assessed by injecting a blank human EDTA plasma sample without IS after injection of the higher limit of quantification 
| Accuracy and precision
Accuracy and within-day and between-day precision were determined by analysing spiked EDTA plasma samples at the LLOQ and HLOQ in addition to three different QC levels (H-M-L) in 5-fold on three different days. For cabozantinib QCXL was also included in this analysis. The accuracy was calculated as the average percentage of the nominal concentration. For the within-day precision the highest coefficient of variation (CV) of the three runs was used. One-way analysis of variance (ANOVA) was used to assess the between-day precision for each of the five concentrations. The error mean square or mean square within groups (ErrMS), the day mean square or mean square among groups (DayMS), and the grand mean (GM) of all 15 measurements across the three run days were obtained from the ANOVA. The estimate of the between-day precision at every concentration was calculated as follows, in which n is the number of replicate measurements within each day:
Between-day precision = ([(DayMS − ErrMS)/n] 0.5 /GM) × 100%.
The within-day and between-day precision was expressed as relative standard deviation (RSD). For the lower limit of quantification, the percent deviation from the nominal concentration and the RSD should be <20%. For all other concentrations the percentage deviation from the nominal concentration and the RSD should be <15%.
| Extraction recovery
Total extraction recovery was determined for all analytes by comparing response ratios of extracted plasma samples with those obtained by direct injection of the same amount of drug in mobile phase at three concentrations (QCH, QCM and QCL) in duplicate. For cabozantinib total extraction recovery was additionally determined for QCXL in duplicate. According to our internal aim, the recovery ratios should be >70% and preferably be constant over the concentration range.
| Dilution integrity
Dilution integrity was investigated for samples with concentrations above the calibration range by analysing samples at a concentrations 1.5 times the HLOQ. Samples were diluted 2 and 4 times, respectively, with blank EDTA plasma. Each dilution was carried out 5-fold and compared with the nominal concentration. Accuracy and precision should be <15%. 
| Matrix effect

| Stability
Stability of the stock solutions in DMSO was tested at −40 C. Spiked samples at three concentrations (QCL, QCM, QCH) were used for determining the stability in plasma (−40 C, 4 C and room temperature). Stability during sample handling was verified by subjecting a range of spiked samples to three freeze-thaw cycles (stored at −40 C). Additionally, autosampler stability over the range of LLOQ to HLOQ of processed samples (4 C) was tested. Stability of individual patient samples was determined in samples that were collected for routine patient care and were stored at −40 C after the initial analysis. Samples within the described limits of accuracy (±15%) were considered to be stable.
| RESULTS
| Method development
The chromatographic separation for the eight analytics is shown in 
| Selectivity and carryover
Multiple reaction monitoring traces of all six blank EDTA plasma samples from individual donors showed the absence of interference as responses were <20% of the LLOQ and 5% of the IS. Chromatograms of all analytes at the LLOQ level and their respective blank human EDTA sample are shown in Figure 3 .
Carryover in the blank sample after injection of the HLOQ sample was <20% of the LLOQ for each drug and <5% of the IS.
| Accuracy and precision
As presented in Table 3 , the accuracy and the within-and betweenday precision over the calibration range (LLOQ, QCXL, QCL, QCM, QCH and HLOQ) met the requirements of a RSD <20% for the LLOQ and a RSD <15% for all other concentrations. Within-day accuracy values for all analytes ranged from 86.8 to 115.0% with a precision <10.4%. Between-day accuracy values ranged between 89.7 and 111.9% with a within-day precision <7.4%.
| Recovery
The total extraction recovery ratios, with protein precipitation used for sample preparation, were >70% and constant over the range of concentrations for all analytes. 
| Dilution integrity
| Matrix effect
The CV of the IS-normalized matrix effect calculated from the six plasma batches at both concentrations (QCL, QCXL for cabozantinib, and QCH) was <8.2% for all analytes.
| Stability
Short-term stability of spiked plasma samples was found to be stable after storage at 4 C and room temperature for at least 14 days. Stability analysis for sample handling showed that samples were stable for F I G U R E 2 Representative reconstructed ion chromatogram overlay of a mixture of the medium quality control samples. 1, niraparib; 2, olaparib; 3, cobimetinib; 4, cabozantinib; 5,dabrafenib; 6, regorafenib M2; 7, vemurafenib; 8, regorafenib at least three freeze-thaw cycles. Processed samples were stable for at least 9 days in the autosampler (4 C).
Long-term stability of the spiked plasma samples stored at −40 C was proven for at least 20 weeks. Stock solutions stored at −40 C remained stable for at least 4.8 months. Samples of patients treated with cabozantinib (n = 2), dabrafenib (n = 6), olaparib (n = 2),niraparib (n = 2) or vemurafenib (n = 1) were stable at −40 C for at least 111, 132, 120, 183 and 132 days, respectively. Stability data are presented in Tables 4 and 5.
| Clinical application
This validated assay is routinely used in our clinic for pharmacokinetic monitoring in patients with cancer. For the anticancer drugs with well-defined target trough levels, therapeutic drug monitoring is implemented as routine service. For anticancer drugs without an established exposure-response relationship, pharmacokinetic evaluation may be performed occasionally for efficacy, toxicity and/or compliance concerns. Our clinic was consulted to determine whether there was sufficient exposure in a patient with progressive disease during treatment with olaparib 400 mg capsules twice daily.
The plasma concentration-time curve for olaparib in this patient is included in Figure 4 . Pharmacokinetic parameters were comparable with the pivotal registration data (Mateo et al., 2016) , confirming adequate exposure. Reconstructed ion chromatograms of patients samples and the internal standard for cabozantinib, olaparib, niraparib and vemurafenib have been included in Supplementary   Figure 1 . In cases where the between-day imprecision is 0.0%, no additional variation upon the within-day imprecision is observed as a result of performing the assay on different days.
| DISCUSSION
In this paper we described the development, validation and application of a UPLC-MS/MS method for the quantification of vemurafenib, cobimetinib, dabrafenib, cabozantinib, regorafenib plus metabolite regorafenib M2, niraparib and olaparib. To our knowledge, this is the first method which measures olaparib and niraparib in combination with the above-mentioned analytes in a single run.
Numerous methods have been developed for the quantification of combinations of tyrosine kinase inhibitors. One of the main difficulties of the analysis of multiple tyrosine kinase inhibitors is the large difference in clinically relevant concentrations for some of them.
Vemurafenib has a target trough concentration of 42,000 μg/L which is several times higher than the levels of other tyrosine kinase inhibitors included in our method (Goldwirt et al., 2016) . Quantification methods of vemurafenib combined with other tyrosine kinase inhibitors that have been previously published, use solid-phase extraction (Rousset et al., 2017) , protein precipitation with methanol followed by a step of evaporation (Cardoso et al., 2018) and protein precipitation with acetonitrile and zinc-sulfate for sample preparation (Huynh et al., 2017 ). An advantage of our analytical method is the simple sample preparation by protein precipitation with acetonitrile. Although the sample preparation is simple, limited matrix effects were observed by this approach. The sample volume of 50 μl is equal to or less than that Rousset et al., 2017; van Andel et al., 2017; van Erp et al., 2013) .
Another major difficulty of the analysis of multiple oral oncolytics in a single run is the wide variety in chemical characteristics of these drugs as shown in Figure 1 . For this reason, almost all of the reported multiple tyrosine kinase inhibitors use a gradient elution system (Cardoso et al., 2018; Huynh et al., 2017; Merienne et al., 2018; Pressiat et al., 2018; van Erp et al., 2013) . Niraparib has a relatively hydrophilic structure and has not yet been included in a multianalyte assay to our knowledge. In our method the analytes are separated adequately to quantify all eight analytes with the use of a gradient system combined with a Cortecs UPLC C18 column. This column tolerates a flow of 0.8 ml/min, which facilitates the relatively short run time of 7 min within the range of previously described runs with multiple tyrosine kinase inhibitors of~5-10 min (Abdelhameed et al., 2017; Cardoso et al., 2018; Huynh et al., 2017; Merienne et al., 2018; Pressiat et al., 2018; van Erp et al., 2013 ).
An important limitation of our method is the need for a set of nine working solutions to reach the range for the calibration standards, which is a labour-intensive approach. However, our method F I G U R E 4 Steady-state plasma concentration-time curve of olaparib in a patient treated with 400 mg capsules twice daily enables simultaneous quantification of eight chemically diverse oral targeted anticancer drugs with a wide range of clinical concentrations and is therefore suitable for application in the clinical setting.
In conclusion, we have developed and validated a robust and UPLC-MS/MS method for the simultaneous quantification of seven new oral anticancer drugs. The assay is used for both guidance of individual patients and for clinical pharmacological trials in our clinic.
